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Abstract 
Background: Customizable orthopaedic implants are often needed for patients with primary malignant bone 
tumors due to unique anatomy or complex mechanical problems. Currently, obtaining customizable orthopaedic 
implants for orthopaedic oncology patients can be an arduous task involving submitting approval requests to the 
Institutional Review Board (IRB) and the Food and Drug Administration (FDA). There is great potential for the delay 
of a patient’s surgery and unnecessary paperwork if the submission pathways are misunderstood or a streamlined 
protocol is not in place.
Purpose: The objective of this study was to review the existing FDA custom implant approval pathways and to deter-
mine whether this process was improved with an institutional protocol.
Methods: An institutional protocol for obtaining IRB and FDA approval for customizable orthopaedic implants was 
established with the IRB at our institution in 2013. This protocol was approved by the IRB, such that new patients only 
require submission of a modification to the existing protocol with individualized patient information. During the two-
year period of 2013–2014, eight patients were retrospectively identified as having required customizable implants 
for various orthopaedic oncology surgeries. The dates of request for IRB approval, request for FDA approval, and total 
time to surgery were recorded, along with the specific pathway utilized for FDA approval.
Results: The average patient age was 12 years old (7–21 years old). The average time to IRB approval of a modifica-
tion to the pre-approved protocol was 14 days (7–21 days). Average time to FDA approval after submission of the 
IRB approval to the manufacturer was 12.5 days (7–19 days). FDA approval was obtained for all implants as compas-
sionate use requests in accordance with Section 561 of the Federal Food Drug and Cosmetic Act’s expanded access 
provisions.
Conclusions: Establishment of an institutional protocol with pre-approval by the IRB can expedite the otherwise 
time-consuming and complicated process of obtaining customizable orthopaedic implants for orthopaedic oncology 
patients.
Level of evidence: Retrospective case series, Level IV. See the Guidelines for authors for a complete description of 
levels of evidence.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
Malignant primary bone tumors are rare entities with 
an incidence of approximately 0.8/100,000 people per 
year. In the adult population, primary malignant bone 
tumors represent 0.2  % of all tumors, whereas in the 
pediatric population, they account for approximately 5 % 
of all malignancies (Kindblom 2009; Dorfman and Czer-
niak 1995). The three most common malignant primary 
bone tumors are osteosarcoma, chondrosarcoma, and 
Ewing’s sarcoma, which combined, represent 75 % of all 
malignant primary bone tumors (Dorfman and Czerniak 
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1995). In the US, osteosarcoma is most common with an 
incidence of approximately 400 cases per year, holding 
the sixth highest prevalence of all cancers in children less 
than fifteen years of age (Mirabello et al. 2009).
When a malignant primary bone tumor is diagnosed, 
patients often require extensive surgery and removal of 
large portions of their skeletal structure along with the 
tumor. Historically, amputation was once the mainstay 
of treatment of these tumors. However, more recent 
advances have made limb salvage surgery feasible (Lewis 
1985; Link et  al. 1986). These procedures require sig-
nificant pre-operative planning, part of which includes 
obtaining an implant appropriate for the patient’s size, 
anatomy, and defect created by the surgery.
Due to the predilection of osteosarcoma for the dis-
tal femur, proximal tibia, and proximal humerus, limb 
length discrepancy can be severe following tumor and 
concomitant physeal resection (Ottaviani and Jaffe 2009). 
The proximal humerus contributes approximately 80  % 
to the final humeral length, the distal femur contributes 
approximately 70  % to the final femoral length, and the 
proximal tibia contributes approximately 57 % to the final 
tibial length (Tsuchihara et al. 2008; Pritchett 1992).
Over the last 2–3 decades, expandable prostheses have 
supplanted older devices due to their ability to simulta-
neously reconstruct the limb and address potential limb 
length discrepancies that may occur in skeletally imma-
ture patients following physeal resection (Eckardt et  al. 
2000; Finn and Simon 1991). Implantation of an expand-
able prosthesis is indicated for limb-salvage in skeletally 
immature patients in which wide resection includes 
removal of an active physis and the patient is left with 
a projected limb-length discrepancy of  ≥6  cm (Harvey 
et  al. 2010; Holm et  al. 1994; Papaioannou et  al. 1982; 
Song et al. 1997; Stanitski 1999). Growth remaining was 
determined according to the standard methods after 
bone age was assessed (Anderson et  al. 1963; Dimeg-
lio 2001). For use in the humerus, the Repiphysis®  was 
discussed with the patient and family as a limb-salvage 
option. As patient size, age, anatomy, and location of 
tumor vary greatly, approved off-the-shelf implants are 
not always available to fit the patient’s needs. Addition-
ally, despite the progress that has been made with respect 
to the design of orthopaedic devices, mechanical failure 
is not uncommon. Failure of one or more components 
of an implanted system may leave the surgeon with a 
unique situation that demands either customization or 
revision components or importation of devices used in 
other parts of the world, which are inherently not FDA 
approved. All devices used in the United States require 
FDA approval prior to implantation, and therefore, this 
creates a distinct logistical challenge for the surgeon.
Pathway overview
The FDA has multiple pathways (Table  1) in place to 
facilitate justified and expeditious acquisition of safe and 
effective implants surgeons or dentists may need. Never-
theless, without proper guidance, it has become some-
what onerous to obtain the implants required, partially 
because of recent increases in manufacturer scrutiny. 
Following a Department of Justice investigation in Sep-
tember 2007, four major orthopaedic companies were 
charged with violating anti-kickback statutes and were 
forced into short-term intense federal monitoring. This 
may have inhibited willingness of manufacturers to pro-
duce custom devices out of residual concern for FDA 
inquiry and assessment of corporate compliance. Addi-
tionally, some surgeons may lack understanding of the 
FDA protocols and when each pathway is applicable. 
Summarized below are the primary pathways relevant to 
obtaining custom orthopaedic surgical implants.
Compassionate use request
The FDA normally allows for unapproved, investigational 
devices to be used in clinical trials with specific criteria 
and specific protocols, under an Investigational Device 
Exemption (IDE). However, it is also possible to use a 
device currently under investigation, but outside of the 
clinical trial, in order to help a patient with a serious or 
life-threatening condition under 21 CFR 812.35-36 and 
Section  561 of the FD&C Act (Investigational Device 
Exemption). Emergency use of unapproved devices is 
allowed, but the sponsor (responsible party) must notify 
the FDA within 5  days following the procedure. The 
“compassionate use” request is a helpful pathway that 
allows physicians to use unapproved devices from clini-
cal trials on patients that do not meet the study’s inclu-
sion criteria, but will benefit from the device. This is 
also known as the “Expanded Access” provision, which 
was included in the FDA Modernization Act of 1997. 
FDA approval is required prior to implementation of the 
device and can be obtained by having the sponsor sub-
mit an IDE supplement including a description of why 
treatment is needed, why alternatives are unsatisfactory, 
any deviations from the clinical protocol, and patient 
protection measures such as IRB approval, institutional 
clearance, informed consent, authorization from the IDE 
sponsor, and independent assessment by an uninvolved 
physician (Investigational Device Exemption 2014).
Custom device exemption
The Custom Device Exemption (CDE) pathway has been 
around since the 1976 amendments to the Federal Food, 
Drug, and Cosmetic Act (FD&C) (Mihalko 2015). The 
pathway was expanded in 2012, under the Food and Drug 
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Administration Safety and Innovation Act (FDASIA) to 
allow for more flexibility in approving devices, but also 
to require annual industry reporting policy (Mihalko 
2015). The guidance document describes that the use of 
custom devices “should represent a narrow category for 
which, due to the rarity of a patient’s medical condition 
or physician’s special need, compliance with premarket 
review requirements and performance standards under 
Sections  514 and 515 of the FD&C Act is impractical.” 
The pathway mandates that to be considered a custom 
device, the device must be created in order to com-
ply with an order of an individual physician, sufficiently 
unique that clinical investigation or performance stand-
ards would not apply, not generally available in the US, 
designed for unique pathology, manufactured on case-
by-case basis or for a unique subset, and produced in 
quantities of less than five per year [this is specified in 
Section 520(b) of the FD&C Act and at 21 CFR 812.3(b)]. 
The five units per year specification refers to five cus-
tom units of a particular type as allowed for production 
by a manufacturer per year. For example, a manufac-
turer would be allowed to produce five patient-specific 
custom implants of a particular device type per year. A 
possible scenario provided in the guidance document for 
appropriate use of this pathway describes a patient with 
skeletal dysplasia requiring a total hip replacement for 
osteoarthritis. A custom implant is needed due to the 
patient’s “unique pathological anatomy.”
Humanitarian use device
A humanitarian use device (HUD) is defined as “a medi-
cal device intended to benefit patients in the treatment or 
diagnosis of a disease or condition that affects or is mani-
fested in fewer than 4000 individuals in the United States 
per year.” A manufacturer of an HUD can be exempt from 
scientifically based validation studies of efficacy man-
dated for standard premarket approval as long as there is 
enough information to suggest that the benefit is prob-
ably greater than the risk and no better alternative exists 
[FD&C Section 520 (m)]. This is known as the Humani-
tarian Device Exemption (HDE). Once a manufacturer 
has obtained an HDE approval for a specific device, IRB 
approval must be obtained from individual institutions, 
which may result in institutional device approval or 
necessitate IRB approval on a case-by-case basis.
Premarket notification [510(k)] and premarket approval 
application
Another pathway the FDA provides for approval of medi-
cal devices is via premarket notification and the premar-
ket approval process. To obtain premarket approval for 
marketing and sale, there must be valid scientific evi-
dence demonstrating the product is safe and effective. For 
premarket notification [510(k)], there must be evidence 
demonstrating a device is as safe as a currently legally 
marketed device. Submitters must compare their device 
to one or more similar legally marketed devices and 
make and support their substantial equivalency claims. A 
device is considered substantially equivalent if it has the 
same intended use and technological characteristics as a 
marketed device, or if it has the same intended use and 
different technological characteristics that does not raise 
new questions of safety and effectiveness. Many ortho-
paedic and implantable cardiac devices are approved via 
supplemental PMA pathways (Rome et  al. 2014; Sheth 
et al. 2009).
Methods
Our institution is a tertiary referral center for patients 
with musculoskeletal tumors. There are three fellow-
ship-trained orthopaedic oncologists on staff. An insti-
tutional protocol has been developed to organize and 
expedite the process of approving the customizable 
orthopaedic implants needed for our patient popula-
tion. We have determined that a customizable implant is 
needed approximately 2–3 times per year in our patient 
population (Beebe et  al. 2009, 2010). Our protocol has 
been designed to satisfy both institutional IRB and FDA 
requirements for customizable implants, and this pro-
tocol has been pre-approved by our institution’s IRB to 
expedite the overall process. Prior to this, we needed to 
submit a new IRB for each patient, which would often 
require a significant amount of paperwork. Under our 
current protocol, when a patient needs a customizable 
implant, a modification to the approved IRB protocol is 
submitted to the IRB for review, which includes infor-
mation regarding the specific rationalization behind our 
request of a customizable implant and a modified con-
sent for surgery and implant usage. Upon IRB approval, 
consent forms, patient specific information, and the 
notice of IRB approval are forwarded to the FDA by our 
staff or the sponsor. After FDA approval, the approval 
letter is provided to the IRB and the surgery is com-
pleted when the implant arrives from the manufacturer, 
consents are signed, and when the patient is ready from 
a medical and/or oncologic standpoint. This protocol 
has been used for 8 retrospectively identified patients 
between 2013 and 2014 (Table 2).
Results
The average patient age was 12 (range 7–21) years old 
at the time of surgery. The pathologic diagnosis of the 
patients was either osteosarcoma or Ewing’s sarcoma. 
Half of the patients required implants for primary tumor 
resection and reconstruction surgeries, and half of the 
customizable implants were for revision surgeries. The 
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most common reason a patient needed a customizable 
implant was because they needed smaller or modified 
Repiphysis (Microport Orthopaedics, Arlington, TN) 
implants due to their age and body size (4/8 patients). For 
patients who underwent a primary procedure, mean time 
to IRB modification approval was 15.75 days (9–21 days). 
For patients who underwent revision, the average time 
to IRB modification approval was 12  days (7–18  days). 
The time required to complete the paperwork for an 
IRB modification is considerably quicker than the usual 
time needed for a new submission. Mean time to FDA 
approval after submission of the IRB approval to the 
sponsor was 10 days (7–15 days) for primary patients and 
15 days (7–19 days) for revision patients. Mean time to 
surgery after FDA approval was 13.75  days (4–28  days) 
for primary patients and 26.5  days (12–44) for revision 
patients. The longest time to surgery of 44 days required 
importation of an implant from a manufacturer in 
Germany.
Many of the patients underwent pre-operative chemo-
therapy during the time period in which the implant 
was being approved. FDA approval was obtained for all 
implants under the “compassionate use” pathway with 
citation of Section  561 of the FD&C act’s expanded 
access provisions. None of the implants were currently 
involved in ongoing clinical trials or had been reviewed 
by the FDA as part of an IDE application.
Discussion
A large portion of our demand for customizable implants 
came from pediatric patients and there was particular 
need for the Repiphysis Limb Salvage System (MicroPort 
Orthopaedics, Arlington, TN). This system has been in 
use since the early 1990s in Europe and has had gener-
ally good to excellent results despite a relatively high 
complication rate (Gitelis et al. 2003; Saghieh et al. 2010). 
Despite its design to address potential limb length dis-
crepancies in skeletally immature patients, we have 
encountered problems requiring requesting customized 
Repiphysis implants that were not previously FDA 
approved. Two of our younger patients were too small for 
their lower extremity implant sizes, one patient needed 
modification of the FDA approved femoral Repiphysis 
due to inadequate femoral bone stock, and two pedi-
atric patients needed Repiphysis implants designed for 
humeral tumors, which are not FDA approved, requir-
ing utilization of the compassionate use pathway. This is 
representative of a longstanding deficiency in the pedi-
atric medical device market, especially for rare pediatric 
conditions. This has primarily been due to insufficient 
financial incentives for companies potentially interested 
in development. A major step forward occurred in 2007 
when the Pediatric Medical Device Safety and Improve-
ment Act was passed to improve post-market surveil-
lance and eliminate profit restrictions on HDE approved 
devices, in an effort stimulate production and innova-
tion. Despite this, many pediatric devices are approved 
on the basis of trials conducted in non-pediatric patients 
(Hwang et al. 2014) and there remains significant under-
development in the pediatric medical device market.
The rest of the implants used required customiza-
tion or modification of existing implants due to unique 
anatomical issues, bone loss, or a complex mechanical 
problem with an existing prosthesis. Because all of these 
situations necessitated modification of existing implants 
and not creation of de novo implants for unique anat-
omy, the “compassionate use” pathway of the Investiga-
tional Device Exemption regulation was appropriate. A 
de novo implant for a unique anatomical problem would 
be best suited by utilizing the Custom Device Exemption 
pathway.
Limitations in this study include the retrospective 
nature of this study, as well as lack of a specific control 
group to compare the time to IRB approval and surgery 
before versus after the establishment of our institutional 
protocol.
Obtaining the customizable orthopaedic implants nec-
essary to promptly and properly treat patients can be 
Table 2 Overview of patients





1 19 Ewing Sarcoma Distal Femur Revision 13 19 44
2 21 Ewing Sarcoma Pelvis Revision 18 7 35
3 11 Osteosarcoma Distal Femur Revision 7 15 12
4 13 Osteosarcoma Prox Humerus Revision 10 19 15
5 7 Osteosarcoma Prox Tibia Primary 12 7 28
6 11 Osteosarcoma Prox Humerus Primary 21 11 8
7 8 Osteosarcoma Distal Femur Primary 9 7 15
8 8 Osteosarcoma Prox Humerus Primary 21 15 4
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complicated and time-consuming. However, with a thor-
ough understanding of the different pathways and their 
indications and a protocol in place with the institution’s 
IRB, the process can be accelerated and less arduous for 
all parties involved.
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